我们曾对原发性胆汁性肝硬变病人用秋水仙硷行双盲对照试验。57例肝活检证实的原发性胆汁性肝硬变患者随机接受每日0.6mg秋水仙硷或等量的安慰剂。病人每隔3个月接受临床及实验室检查和每年作一次肝活检。第4年时两组的AKP与ALT均值有显著的统计学差异。治疗组的胆红素和IgM值虽有所下降,但无统计学意义。治疗组与对照组比较,AKP均值下降明显,从281至112IU/L(P<0.01)。同样,ALT值 We used a double-blind, controlled trial of colchicine in patients with primary biliary cirrhosis. Fifty-seven patients with primary biliary cirrhosis confirmed by liver biopsy were randomized to receive either 0.6 mg colchicine per day or an equal amount of placebo. Patients undergo clinical and laboratory examinations every 3 months and liver biopsies are performed annually. There was a statistically significant difference between the mean AKP and ALT at 4 years in both groups. Although the bilirubin and IgM values ​​of the treatment group decreased, they were not statistically significant. Compared with the control group, the AKP decreased significantly from 281 to 112 IU / L in the treatment group (P <0.01). Again, the ALT value